荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

已收盘 05-06 16:08:49

30.000

+0.200

+0.67%

最高30.900	最低29.100	成交量154.98万
今开29.500	昨收29.800	日振幅6.04%
总市值163.28亿	流通市值56.87亿	总股本5.44亿
成交额4,691万	换手率0.82%	流通股本1.90亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":30,"timestamp":1714982929021,"preClose":29.8,"halted":0,"volume":1549814,"delay":0,"floatShares":189581239,"shares":544263003,"eps":-3.0357332,"marketStatus":"已收盘","marketStatusCode":5,"change":0.2,"latestTime":"05-06 16:08:49","open":29.5,"high":30.9,"low":29.1,"amount":46908438,"amplitude":0.060403,"askPrice":30,"askSize":16500,"bidPrice":29.85,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":-3.0902864776315377,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715045400000},"adr":0,"listingDate":1604851200000,"adjPreClose":29.8,"openAndCloseTimeList":[[1714959000000,1714968000000],[1714971600000,1714982400000]],"volumeRatio":1.189026,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":58.03,"timestamp":1714978800000,"preClose":55.55,"halted":0,"volume":2746559,"delay":0,"premium":"-52.32"}},"requestUrl":"/m/hq/s/09995/wiki","defaultTab":"wiki","newsList":[{"id":"2433696964","title":"北向资金4月30日净买入荣昌生物8.94万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2433696964","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2433696964?lang=zh_cn&edition=full","pubTime":"2024-05-06 09:30","pubTimestamp":1714959034,"startTime":"0","endTime":"0","summary":"4月30日, 北向资金增持荣昌生物8.94万股，连续3日增持。截止当日收盘，沪股通共持有荣昌生物173.41万股，占流通股1.07%。沪股通增持金额前五个股分别为江苏银行、中远海控、招商银行、中国石油、赤峰黄金。荣昌生物近5个交易日上涨3.20%，沪股通累计增持20.19万股；近20个交易日上涨3.12%，沪股通累计增持13.90万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050609361087d64666&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050609361087d64666&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432643142","title":"【券商聚焦】中泰证券首予荣昌生物(09995)“买入”评级 指其具备研发到商业化全链条能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2432643142","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2432643142?lang=zh_cn&edition=full","pubTime":"2024-05-02 14:11","pubTimestamp":1714630271,"startTime":"0","endTime":"0","summary":"2个产品已上市，在多项临床研究中读出亮眼数据。采用分部估值法，荣昌生物总计估值241亿元，取1人民币=1.1港元，总计估值265亿港元，首次覆盖，给予“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20200915/N2I1NTQ1N2YyMmRiZjBmNTUwMDA0Njc2Mzg1.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/N2I1NTQ1N2YyMmRiZjBmNTUwMDA0Njc2Mzg1.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1936164","is_publish_highlight":false,"gpt_icon":0},{"id":"2432643377","title":"港股异动 | 基石药业-B(02616)涨超26%领涨创新药概念 ASCO催化行情 机构看好政策+医保边际向上","url":"https://stock-news.laohu8.com/highlight/detail?id=2432643377","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432643377?lang=zh_cn&edition=full","pubTime":"2024-05-02 13:56","pubTimestamp":1714629376,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，创新药概念股表现强势，截至发稿，基石药业-B涨26.14%，报1.11港元；康希诺生物涨16.91%，报20.95港元；加科思-B涨14.2%，报1.93港元；诺诚健华涨12.31%，报5.2港元；荣昌生物涨10.2%，报30.8港元。浙商证券指出，2023年创新药医保谈判结果高成功率及温和降幅，体现出政策对创新药倾斜与支持，我们期待更多的创新药行业规范化以及支持的政策推进。创新药已形成较为稳定的谈判节奏和价格预期，我们持续看好创新药行业中长期的投资机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116861.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432691554","title":"荣昌生物(09995)上涨5.01%，报29.35元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432691554","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432691554?lang=zh_cn&edition=full","pubTime":"2024-05-02 10:22","pubTimestamp":1714616575,"startTime":"0","endTime":"0","summary":"5月2日，荣昌生物(09995)盘中上涨5.01%，截至10:22，报29.35元/股，成交141.47万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年一季报，荣昌生物营业总收入3.3亿元、净利润-3.49亿元。4月30日，浦银国际证券维持中性评级,目标价33港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/02102240508981.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432999856","title":"荣昌生物盘中异动 股价大涨5.01%报29.351港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432999856","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432999856?lang=zh_cn&edition=full","pubTime":"2024-05-02 10:22","pubTimestamp":1714616570,"startTime":"0","endTime":"0","summary":"2024年05月02日早盘10时22分，荣昌生物股票出现异动，股价急速上涨5.01%。截至发稿，该股报29.351港元/股，成交量4.95万股，换手率0.03%，振幅4.83%。荣昌生物股票所在的生物技术行业中，整体跌幅为0.01%。抗体偶联药物领域的领军企业荣昌生物近日发布了2024年第一季度财务报告，期内公司营业收入实现3.3亿元，同比上一年度同期增长96.41%，然而归母净利润亏损约3.49亿元，较2023年同期的3.24亿元亏损有所扩大。2023年，荣昌生物全年研发费用高达13.06亿元，同比增长33.01%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021022517a57e4e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021022517a57e4e4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431736173","title":"荣昌生物(09995)1Q24净亏损符合预期，公司维持2024年收入指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2431736173","media":"浦银国际证券","top":-1,"share":"https://www.laohu8.com/m/news/2431736173?lang=zh_cn&edition=full","pubTime":"2024-04-30 15:14","pubTimestamp":1714461252,"startTime":"0","endTime":"0","summary":"公司维持2024年收入指引。我们维持“持有”评级和目标价33港元。毛利率达到77.5%，较4Q23略微下降0.5个百分点。维持2024年收入同比增长50%的指引：根据我们与公司最近的沟通，公司维持年报业绩会给出的2024年指引，即整体收入同比增长50%，包括两款上市产品收入均增长50%以上，其中RC18有望增速略快于RC48。审批完成后，公司会根据股价情况决定是否发行定增。若年内RC18或RC88能够实现出海，则公司股票有望迎来主要上调机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043015305587c2af46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043015305587c2af46&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431865161","title":"近两年亏损近25亿后抛出25.5亿定增，荣昌生物钱都花哪去了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2431865161","media":"山东财经头条","top":-1,"share":"https://www.laohu8.com/m/news/2431865161?lang=zh_cn&edition=full","pubTime":"2024-04-29 21:18","pubTimestamp":1714396691,"startTime":"0","endTime":"0","summary":"2023年2月，荣昌生物超过95元/股。据了解，2020年荣昌生物港股上市时，募资净额约37.85亿元；2022年A股上市时，又募集了约25.06亿元，共计募资近63亿元。近3年投入超30亿用于研发作为国内首款原创ADC新药的拥有者，荣昌生物的高光时刻集中在2021年至2022年。2023年，荣昌生物的销售费用大幅提升，达7.75亿元，较2022年的4.41亿元同比增加75.9%。而在2021年，荣昌生物的销售费用也达到2.63亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042921302287bf9908&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042921302287bf9908&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431006410","title":"荣昌生物04月29日遭主力抛售352万元 环比增加147.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431006410","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431006410?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:15","pubTimestamp":1714378544,"startTime":"0","endTime":"0","summary":"04月29日, 荣昌生物股价跌8.69%，报收27.85元，成交金额9055万元，换手率1.66%，振幅12.79%，量比2.45。荣昌生物今日主力资金净流出352万元，上一交易日主力净流出142万元，今日环比增加147.89%。该股近5个交易日下跌1.76%，主力资金累计净流出399万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入6万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042916161387be2eaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042916161387be2eaf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431081480","title":"荣昌生物（09995.HK；688331.SH）：2024年一季度亏损扩大至3.49亿元，营收同比增长96.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431081480","media":"和讯","top":-1,"share":"https://www.laohu8.com/m/news/2431081480?lang=zh_cn&edition=full","pubTime":"2024-04-29 14:40","pubTimestamp":1714372815,"startTime":"0","endTime":"0","summary":"荣昌生物一季报显示亏损扩大，营收同比增长抗体偶联药物领域的领军企业荣昌生物近日发布了2024年第一季度财务报告，期内公司营业收入实现3.3亿元，同比上一年度同期增长96.41%，然而归母净利润亏损约3.49亿元，较2023年同期的3.24亿元亏损有所扩大。2023年营收增长但亏损额度增加荣昌生物的2023年年报亦显示出公司营业收入达到10.83亿元，同比增加了40.26%。研发与销售费用持续增长2023年，荣昌生物全年研发费用高达13.06亿元，同比增长33.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042914420487bdca6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042914420487bdca6a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431021444","title":"港股异动 | 荣昌生物(09995)跌超7% 一季度亏损同比扩大至3.49亿元 此前宣布拟定增25.5亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2431021444","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431021444?lang=zh_cn&edition=full","pubTime":"2024-04-29 11:19","pubTimestamp":1714360788,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物跌超7%，截至发稿，跌7.54%，报28.2港元，成交额4831.39万港元。消息面上，荣昌生物公布2024年第一季度业绩，营业收入约3.3亿元，同比增长96.41%；归属于上市公司股东的净亏损约3.49亿元，同比扩大约7.77%。荣昌生物2023年财报显示，期内公司净亏损约15.11亿元，同比扩大51.3%。此前荣昌生物发布定增公告，宣布拟募集资金25.5亿元用于创新药物的研究与开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1113917.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431023284","title":"荣昌生物(09995)下跌5.25%，报28.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431023284","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431023284?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:37","pubTimestamp":1714358235,"startTime":"0","endTime":"0","summary":"4月29日，荣昌生物(09995)盘中下跌5.25%，截至10:37，报28.9元/股，成交2732.32万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年一季报，荣昌生物营业总收入3.3亿元、净利润-3.49亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/29103740460020.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431004041","title":"荣昌生物(09995.HK)首季亏损扩大至3.5亿元人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2431004041","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431004041?lang=zh_cn&edition=full","pubTime":"2024-04-29 10:08","pubTimestamp":1714356480,"startTime":"0","endTime":"0","summary":"荣昌生物(09995.HK) 公布，第一季净亏损约3.49亿元人民币(下同)，对比去年同期亏损3.24亿元，每股亏损65分。营业收入3.3亿元，按年升96.4%，主要因为泰它西普和维迪西妥单抗销量增加。(cy/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-26 16:25。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210305144102705_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210305144102705_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345762/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2430065496","title":"《业绩》荣昌生物(09955.HK)首季度亏损扩至3.49亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2430065496","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430065496?lang=zh_cn&edition=full","pubTime":"2024-04-28 22:55","pubTimestamp":1714316100,"startTime":"0","endTime":"0","summary":"荣昌生物(09955.HK) 公布3月止第一季度报告，按中国会计准则，实现营业收入3.3亿人民币(下同)，按年增加96.4%。亏损由上年同期3.24亿元，扩至3.49亿元，每股亏损65分。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-26 16:25。)过往派息公布日期派息事项派息内容2024/03/21末期业绩无派息2023/08/18中期业绩无派息2023/03/22末期业绩无派息 2022/08/18中期业绩无派息 AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20201021142610603_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20201021142610603_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1345627/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2430140437","title":"荣昌生物一季度亏损3.49亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430140437","media":"北京商报官方账号","top":-1,"share":"https://www.laohu8.com/m/news/2430140437?lang=zh_cn&edition=full","pubTime":"2024-04-27 20:13","pubTimestamp":1714220018,"startTime":"0","endTime":"0","summary":"北京商报讯（记者 姚倩）4月27日，荣昌生物发布2024年一季度业绩公告称，由于公司泰它西普和维迪西妥单抗销量增加，公司实现营收约3.3亿元，同比增加96.41%；亏损约3.49亿元。同日，荣昌生物发布公告称，鉴于“生物新药产业化项目”募集后承诺募集资金投资金额已经全部投入，公司拟将上述募投项目节余募集资金 1114.71 万元（具体金额以资金转出当日专户余额为准）永久补充流动资金，用于公司日常生产经营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404272015138b5a8fda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404272015138b5a8fda&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430537784","title":"图解荣昌生物一季报：第一季度单季净利润同比减7.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430537784","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2430537784?lang=zh_cn&edition=full","pubTime":"2024-04-27 02:10","pubTimestamp":1714155042,"startTime":"0","endTime":"0","summary":"证券之星消息，荣昌生物2024年一季报显示，公司主营收入3.3亿元，同比上升96.41%；归母净利润-3.49亿元，同比下降7.77%；扣非净利润-3.46亿元，同比下降4.15%；负债率43.81%，投资收益4.53万元，财务费用1071.17万元，毛利率77.5%。财报数据概要请见下图: 以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700003786.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430927952","title":"荣昌生物(09995)公布一季度业绩 归母净亏损约3.49亿元 同比扩大约7.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430927952","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2430927952?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:37","pubTimestamp":1714135035,"startTime":"0","endTime":"0","summary":"荣昌生物(09995)公布2024年第一季度业绩，营业收入约3.3亿元，同比增长9...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_27.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_27.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112269.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430275375","title":"荣昌生物(688331.SH)发布一季度业绩 净亏损3.49亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430275375","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430275375?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:05","pubTimestamp":1714133107,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(688331.SH)披露2024年第一季度报告，该公司报告期实现营业收入3.30亿元，同比增长96.41%。归属于上市公司股东的净亏损3.49亿元，归属于上市公司股东的扣除非经常性损益的净亏损3.46亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1112190.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430241913","title":"ADC赛道投资分水岭显现，“错锋竞争+造血研发”成新风向标？","url":"https://stock-news.laohu8.com/highlight/detail?id=2430241913","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430241913?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:18","pubTimestamp":1714119495,"startTime":"0","endTime":"0","summary":"今年4月3日，丹麦药企Genmab宣布将以18亿美元全现金交易形式收购一家中国本土的ADC药物研发Biotech普方生物，从而获得其自主研发的ADC技术资产。此前国金证券公布的一份研报也显示，国内ADC在研药物有超过60个是靶向HER2，位居首位。但在强调差异化的ADC赛道，聚集成熟靶点并非一件好事，随着市场竞争趋于白热化，研发企业能否从有限的适应症市场分得一杯羹成为一个未知数，也影响市场对公司后续价值的判断。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1111461.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430443247","title":"港股异动 | 创新药概念股走高 科济药业-B(02171)涨超11% 创新药迎来全流程支持机制","url":"https://stock-news.laohu8.com/highlight/detail?id=2430443247","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430443247?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:17","pubTimestamp":1714015021,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，创新药概念股持续走高，截至发稿，科济药业-B(02171)涨10.3%，报5.57港元；来凯医药-B(02105)涨9.15%，报6.44港元；荣昌生物(09995)涨6.29%，报31.25港元；君实生物(01877)涨5.65%，报10.28港元。甬兴证券指出，2023年医保基金运行总体平稳，该行认为随着国家医保局建立覆盖申报、评审、测算、谈判等全流程的创新药支持机制，更多新药好药有望纳入医保，创新药研发相关企业有望受益。东海证券表示，今年以来包括对创新药的明确支持、集采续约条款的持续优化等，行业政策向好态势明显；二季度以后板块整体有望持续转暖向好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109550.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430443437","title":"科济药业、荣昌生物大涨！恒生医药ETF再度涨超2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430443437","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2430443437?lang=zh_cn&edition=full","pubTime":"2024-04-25 11:13","pubTimestamp":1714014780,"startTime":"0","endTime":"0","summary":"随着港股市场持续回暖，相关ETF本周交投火热，恒生互联网ETF（513330）、恒生科技指数ETF（513180）近日霸榜跨境型ETF成交额榜一、榜二。港股医药板块今日强势领涨，科济药业、荣昌生物、百济神州、乐普生物等强势领涨。恒生医药ETF（159892）则在上周五触及历史底部后已连续4个交易日涨幅突破2%，今日盘中涨幅一度上榜全市场前三！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404251115307a557685&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404251115307a557685&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.023},{"period":"1month","weight":0.0171},{"period":"3month","weight":0.8215},{"period":"6month","weight":-0.3212},{"period":"1year","weight":-0.3046},{"period":"ytd","weight":-0.2043}],"compareEarnings":[{"period":"1week","weight":0.0467},{"period":"1month","weight":0.1047},{"period":"3month","weight":0.1894},{"period":"6month","weight":0.046},{"period":"1year","weight":-0.0738},{"period":"ytd","weight":0.0838}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事创新型生物药研发和制造的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单克隆抗体及双特异性抗体等治疗性抗体药物的发现、开发与商业化。该公司的主要产品包括泰它西普（RC18）、维迪西妥单抗（RC48）和双靶点融合蛋白（RC28）。该公司的产品主要应用于治疗自身免疫疾病、肿瘤和眼科等重大疾病。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.188174},{"month":2,"riseRate":0.75,"avgChangeRate":0.173193},{"month":3,"riseRate":0.25,"avgChangeRate":-0.108046},{"month":4,"riseRate":0.75,"avgChangeRate":-0.020996},{"month":5,"riseRate":0.5,"avgChangeRate":-0.056127},{"month":6,"riseRate":1,"avgChangeRate":0.180883},{"month":7,"riseRate":0.666667,"avgChangeRate":0.049642},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.052805},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.023458},{"month":10,"riseRate":0.666667,"avgChangeRate":0.128837},{"month":11,"riseRate":1,"avgChangeRate":0.035442},{"month":12,"riseRate":0.5,"avgChangeRate":0.023444}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}